Welcome to our dedicated page for COSCIENS Biopharma SEC filings (Ticker: CSCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on COSCIENS Biopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into COSCIENS Biopharma's regulatory disclosures and financial reporting.
COSCIENS Biopharma Inc. removed 10,190,859 registered common shares and related purchase rights from its Form F-1 registration by filing Post-Effective Amendment No. 6.
The amendment states the company terminated the offering under Registration Statement File No. 333-248561 and, consistent with its undertakings, is terminating effectiveness and removing any unsold securities. The original registration covered shares issuable on exercise of certain unregistered warrants exercisable through February 5, 2026 and August 3, 2025.
COSCIENS Biopharma Inc. terminates the Form F-1 offering that had registered up to 14,457,831 units with a proposed aggregate offering price of up to $12,000,000.
This Post-Effective Amendment No. 6 deregisters and removes from registration any unsold registered Units, Pre-Funded Units, Common Warrants, Placement Agent Warrants and the underlying Shares as of the amendment's effectiveness.
COSCIENS Biopharma Inc. filed Post-Effective Amendment No. 1 to its Form F-1 to terminate the offering and deregister securities previously registered under Registration No. 333-277115.
The original Registration Statement registered the issuance of up to 633,583 common share purchase warrants and up to 633,583 Shares issuable upon exercise of those Warrants, of which 579,037 Warrants were issued to Shareholders and 54,546 Warrants were issued to Existing Warrant Holders. The amendment terminates the offering in the United States and removes from registration any and all securities remaining unsold as of the effective date of this Post-Effective Amendment.
COSCIENS Biopharma Inc. has filed Post-Effective Amendment No. 6 to its Form F-1 to terminate the offering and remove from registration any unsold securities under Registration Statement No. 333-239019. The original registration, declared effective June 16, 2020, had registered up to 6,177,174 common shares issuable upon exercise of certain warrants. This amendment, signed March 13, 2026, states the Company has terminated the offering and removes all securities remaining unsold as of effectiveness.
COSCIENS Biopharma Inc. has decided to stop funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The Company expects these entities to enter a structured insolvency process and to surrender its rights to Macrilen, its main FDA and EMA approved pharmaceutical asset.
Management explains that Macrilen and the broader biopharmaceutical business have operated at a loss, and a failed Phase 3 DETECT trial for a pediatric indication in the U.S. undermined growth plans. COSCIENS plans to significantly cut ongoing operating expenses and focus on its plant-based active ingredients business, including avenanthramides and beta glucan used in skincare products.
COSCIENS Biopharma Inc. filed a report describing an upcoming special meeting of its security holders. The company, through its transfer agent Computershare, set March 3, 2026 as the record date for notice and voting, with the meeting scheduled for April 7, 2026 as a virtual event.
The filing also reiterates extensive forward-looking statement cautions, highlighting risks related to its patented technologies, nutraceutical and pharmaceutical product development, facility build-outs, liquidity and capital resources, and overall business strategy. Common shares are identified as the voting security for this special meeting.
COSCIENS Biopharma Inc. furnished a Form 6-K that includes its Q3 2025 interim financial materials and related certifications. The filing lists Exhibits 99.1–99.4, covering condensed interim consolidated financial statements for the third quarter of 2025, management’s discussion and analysis, and CEO/CFO certifications under National Instrument 52-109.
The exhibits are incorporated by reference into the company’s existing Form S-8 registration statements and are deemed part of those filings from the date this Form 6-K is furnished. The company also includes forward-looking statements and directs readers to risk factors in its most recent Annual Report on Form 20-F.
COSCIENS Biopharma Inc. furnished a Form 6-K noting it issued a press release with third quarter 2025 results and a strategic update, including a voluntary delisting from the Nasdaq Capital Market while maintaining its listing on the Toronto Stock Exchange.
The press release is attached as Exhibit 99.1 and is incorporated by reference into the company’s Registration Statements on Form S-8 (Nos. 333-224737, 333-210561, 333-200834, 333-279844). The filing reiterates forward-looking statement cautions and points investors to existing risk factors in its most recent Form 20-F and other filings.